CoChat

Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria

Open access
Taylor, Walter R. J., Kim, Saorin, Kheng, Sim, Muth, Sinoun, Tor, Pety, Christophel, Eva, Mukaka, Mavuto, Kerleguer, Alexandra, Luzzatto, Lucio, Baird, J. Kevin, Menard, Didier · 2021 · PLOS Neglected Tropical Diseases

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.

Abstract

Background: Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery. Little is known how malaria affects glucose-6-phosphate dehydrogenase (G6PD) activity and whether changes in activity when patients present may lead qualitative tests, like the fluorescent spot test (FST), to misdiagnose G6PD deficient (G6PDd) patients as G6PD normal (G6PDn). Giving primaquine or tafenoquine to such patients could result in severe haemolysis. Methods: We investigated the G6PD genotype, G6PD enzyme activity over time and the baseline FST phenotype in Cambodians with acute P . vivax malaria treated with 3-day dihydroartemisinin piperaquine and weekly primaquine, 0·75 mg/kg x8 doses. Results: Of 75 recruited patients (males 63), aged 5–63 years (median 24), 15 were G6PDd males (14 Viangchan, 1 Canton), 3 were G6PD Viangchan heterozygous females, and 57 were G6PDn; 6 patients had α/β-thalassaemia and 26 had HbE. Median (range) Day0 G6PD activities were 0·85 U/g Hb (0·10–1·36) and 11·4 U/g Hb (6·67–16·78) in G6PDd and G6PDn patients, respectively, rising significantly to 1·45 (0·36–5·54, p<0.01) and 12·0 (8·1–17·4, p = 0.04) U/g Hb on Day7, then falling to ~Day0 values by Day56. Day0 G6PD activity did not correlate (p = 0.28) with the Day0 reticulocyte counts but both correlated over time. The FST diagnosed correctly 17/18 G6PDd patients, misclassifying one heterozygous female as G6PDn. Conclusions: In Cambodia, acute P . vivax malaria did not elevate G6PD activities in our small sample of G6PDd patients to levels that would result in a false normal qualitative test. Low G6PDd enzyme activity at disease presentation increases upon parasite clearance, parallel to reticulocytosis. More work is needed in G6PDd heterozygous females to ascertain the effect of P . vivax on their G6PD activities. Trial registration: The trial was registered (ACTRN12613000003774) with the Australia New Zealand Clinical trials ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363399&isReview=true ).

Overview

CoChat Summary

TL;DR

In Cambodian patients with acute *P. vivax* malaria treated with dihydroartemisinin-piperaquine and weekly primaquine, G6PD activity rose modestly by Day 7 in both G6PD-deficient and G6PD-normal patients and returned toward baseline by Day 56, without elevating G6PD-deficient patients into the normal range. The fluorescent spot test correctly identified 17/18 G6PD-deficient patients, misclassifying one heterozygous female as normal.

Key findings

  • Among 75 recruited patients (63 males; median age 24, range 5–63), 15 were G6PD-deficient males (14 Viangchan, 1 Canton), 3 were G6PD Viangchan heterozygous females, and 57 were G6PD normal; 6 had α/β-thalassaemia and 26 had HbE.
  • Median Day 0 G6PD activity was 0.85 U/g Hb (0.10–1.36) in G6PD-deficient patients and 11.4 U/g Hb (6.67–16.78) in G6PD-normal patients, rising significantly by Day 7 to 1.45 U/g Hb (0.36–5.54, p<0.01) and 12.0 U/g Hb (8.1–17.4, p=0.04), respectively, then falling to ~Day 0 values by Day 56.
  • Day 0 G6PD activity did not correlate with Day 0 reticulocyte counts (p=0.28), but over time G6PD activity was explained only by changes in reticulocyte counts in mixed-effects modelling (coefficient 0.29, 95% CI 0.039–0.52, p=0.024).
  • The fluorescent spot test correctly diagnosed 17/18 G6PD-deficient patients (sensitivity 94.4%, 95% CI 72.7–99.8) and 55/57 G6PD-normal patients (specificity 96.5%, 95% CI 87.9–99.6), misclassifying one heterozygous female as G6PD normal.

Methods

  • From January 2013 to January 2014, 75 non-pregnant Cambodians aged >1 year with uncomplicated *P. vivax* received dihydroartemisinin-piperaquine on Days 0–2 and eight weekly primaquine doses (0.75 mg/kg, Days 0–49); 67 completed follow-up to Day 56.
  • Assessments included G6PD genotype by PCR, G6PD enzyme activity, baseline fluorescent spot test, reticulocyte counts, haemoglobin, Hb electrophoresis, full blood count and routine biochemistry at Days 0, 7, 28, and 56; G6PD activity in thalassaemic patients was adjusted for low mean corpuscular volume.
  • Analysis used Stata v14 with chi-squared/Fisher tests, paired/unpaired t or non-parametric tests, FST sensitivity/specificity against genotype, backward stepwise multivariate regression, linear mixed-effects modelling, and Pearson correlation.

Limitations

  • The authors state the study was limited by the small number of G6PD-deficient patients, very few G6PD-deficient heterozygous females, and almost all having one variant (G6PD Viangchan); more data are needed across variants and in heterozygous females, and in falciparum-infected patients.
  • The authors state there was no no-primaquine arm, which would have helped separate effects of malaria itself and its treatment on G6PD activity and reticulocyte counts over time.
  • Evident from the text: four inappropriately low G6PD-normal values were excluded (probably due to delayed analysis) and 39 values were missing due to loss to follow-up or not being done; one heterozygous female’s Day 0 value may have been spuriously low for technical reasons.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pntd.0009690

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Time course of G6PD activity and reticulocyte counts in male vivax-infected patients given weekly primaquine. Panel A: G6PD activity. Panel B: reticulocyte counts.
Fig 1 Time course of G6PD activity and reticulocyte counts in male vivax-infected patients given weekly primaquine. Panel A: G6PD activity. Panel B: reticulocyte counts.CC BY · PubMed Central
Fig 2 Time course of G6PD activity and reticulocyte counts in female vivax-infected patients given weekly primaquine. Panel A: G6PD activity. Panel B: reticulocyte counts.
Fig 2 Time course of G6PD activity and reticulocyte counts in female vivax-infected patients given weekly primaquine. Panel A: G6PD activity. Panel B: reticulocyte counts.CC BY · PubMed Central
Fig 3 Relationship between the percentage changes in G6PD activity and percentage changes in reticulocyte counts between Day 7 and baseline in the two G6PD groups. Panel A: G6PD normal patients: the Pearson correlation coefficient, r, was 0.14, adjusted R2 0.34 (p<0.001). Panel B: G6PD deficient patients: r = 0.063, aR2 = -0.063 (p = 0.64).
Fig 3 Relationship between the percentage changes in G6PD activity and percentage changes in reticulocyte counts between Day 7 and baseline in the two G6PD groups. Panel A: G6PD normal patients: the Pearson correlation coefficient, r, was 0.14, adjusted R2 0.34 (p<0.001). Panel B: G6PD deficient patients: r = 0.063, aR2 = -0.063 (p = 0.64).CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 18 Not checked · 39 Own results and interpretations

15 more claims

Create a free account to see all 57 claims and to verify the 34 references still open.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 10
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Research works printed but not linked: 1

  1. JD Brito-Sousa, 2019, Clinical Spectrum of Primaquine-induced Hemolysis in G6PD Deficiency: A Nine-Year Hospitalization-Based Study from the Brazilian Amazon, Clinical infectious diseases: an official publication of the Infectious Diseases Society of America

Cited by

See all 9

Metadata

Authors
Taylor, W. R. J., Kim, S., Kheng, S., Muth, S., Tor, P., Christophel, E., Mukaka, M., Kerleguer, A., Luzzatto, L., Baird, J. K., & Menard, D.
Affiliations
  • Cambodia National Malaria Center (KH)
  • Institut Pasteur du Cambodge (KH)
  • World Health Organization Regional Office for the Western Pacific (PH)
  • University of Oxford (GB)
  • Muhimbili University of Health and Allied Sciences (TZ)
  • Eijkman Institute for Molecular Biology (ID)
Corresponding author
Taylor, Walter R. J.
Venue
PLOS Neglected Tropical Diseases
Published
2021-09-08
Volume
15
Issue
9
Pages
e0009690
ISSN
  • 1935-2727 (ISSN-L)
  • 1935-2735
OpenAlex
W3197377802
Cited by
9
References
35
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2022: 3
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • PLoS neglected tropical diseases (publishedVersion, cc-by)
  • Oxford University Research Archive (ORA) (University of Oxford) (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • World Health Organization
  • France Expertise International
  • Wellcome Trust (B9RJIXO)
  • French Ministry of Foreign Affairs
  • APMEN fellowship grant (103-09)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords
glucose-6-phosphate dehydrogenase, glucose-6-phosphate dehydrogenase deficiency, vivax malaria, primaquine, tafenoquine, hemolysis, reticulocytosis, reticulocyte count, fluorescent spot test, dihydroartemisinin-piperaquine, thalassemia, HbE, Cambodia
MeSH terms
Adolescent, Adult, Aged, Antimalarials, Cambodia, Child, Child, Preschool, Erythrocytes, Female, Genotype, Glucosephosphate Dehydrogenase, Hemoglobins, Hemolysis, Humans, Male, Middle Aged, Primaquine, Malaria, Vivax, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.